PLRZ

Polyrizon Ltd. (PLRZ) | Rumor.io

Polyrizon

PLRZ

Attention (50-day avg)0%

Attention rank (50-day avg)#3,292

Bullish sentiment (50-day avg)67%

Price to earnings ratio0

Market capitalization24.9M

Earnings per share-4.9

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-3.3M

Social

What share of all stock conversation is about PLRZ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jul 7

A dedicated group for $PLRZ holders is now online, open to investors holding PolyRizon Ltd. stock to discuss the stock and get the latest information.
No other market-relevant information is available from this post.
The post does not mention any specific events, updates, or news related to PolyRizon Ltd. or its stock.

Generated by AI

Sentiment

Of the messages about PLRZ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	60% -8.75	83.13% +3.57
Bearish	—	100% new	40% +8.75	16.87% -3.57

Bullish· Feb 2

$PLRZ has broken key resistance levels, with a +31.36% surge to $15.12, confirming institutional accumulation and targeting $20.96.
The NASARIX™ usability study is advancing the regulatory pathway, providing a catalyst for Polyrizon Ltd.'s momentum and fueling a powerful technical breakout.
Polyrizon Ltd.'s stock is showing strong momentum, with a +36.22% surge to $15.68, and is on track to reach its next target of $22.43, driven by the company's progress in the FDA usability study for NASARIX™.

Bearish· Dec 8

The asset has a thin float, making it susceptible to large price movements.
A significant portion of the asset's volume is off-exchange, which may indicate a lack of liquidity.
The asset's price has fallen by as much as 30% and is experiencing heavy selling pressure.

Generated by AI

Topics

Of the messages about PLRZ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	50%	76.92%	10.48%
Technical Analysis	—	50%	15.38%	19.33%
Controversies	—	0%	7.69%	0.04%
Analysts	—	0%	0%	33.84%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	36.32%

Announcements· Apr 15

Polyrizon Ltd. ($PLRZ) has closed a $3.5 million registered direct offering and concurrent private placement.
The offering will provide Polyrizon Ltd. with additional capital to support its business operations.
The company did not disclose any specific details on how the funds will be used.

Technical Analysis· Jan 4

The stock broke through the $10.12 resistance level on high volume, suggesting a potential major run.
The news about the nasal spray is adding fuel to the stock's upward momentum.
The target price in play is $19.64.

Generated by AI

Community

Of the messages about PLRZ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	66.67%	16.61%
Newcomers	—	0%	33.33%	83.39%

Apr 15

Polyrizon Ltd. has closed a $3.5 million registered direct offering and concurrent private placement.
This funding round will help the company continue its growth and development in the biopharmaceutical industry.
The exact terms and details of the funding round are not specified in the provided information.

Generated by AI

RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the closing of its previously announced registered direct offering and concurrent private placement. The Company issued to a single institutional investor Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also i

26d agoYahoo Finance

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

1mo agoBarchart.com

Also Discussed

Investors talking about PLRZ also mention

#	Name	Attention
1	SMX (Security Matters) Public Limited CompanySMX	0%+0
2	AMC Robotics CorporationAMCI	0%0
3	Fitell Corp.FTEL	0%0
4	Atif Holdings Ltd.ZBAI	0%0
5	Beasley Broadcast Group IncBBGI	0%new
6	DMN - Damon Inc. Common Stock	——
7	Wang & Lee Group Inc.WLGS	0%0
8	ECDA - ECD Automotive Design, Inc.	——
9	NUKK - Nukkleus Inc.	——
10	Healthcare Triangle Inc.HCTI	0%0

Polyrizon Ltd.

Healthcare
Biotechnology

Polyrizon Ltd. is an Israel-based biotechnology company focused on developing innovative intranasal protective products. The company specializes in medical device hydrogels delivered as nasal sprays that form a thin barrier in the nasal cavity, designed to help prevent viruses, allergens, and other airborne particles from contacting nasal tissue. Its proprietary Capture and Contain technology is intended to create a temporary shield in the nose, while its Trap and Target platform supports intranasal delivery of active pharmaceutical ingredients. Polyrizon also develops product candidates aimed at nasal allergy blocking and influenza protection. In addition to preventative intranasal solutions, the company works on improving bioadhesion and retention characteristics for drug delivery applications. Polyrizon Ltd. serves the healthcare and biotechnology markets through research, development, and commercialization of nasal-care technologies.

Website

Location

5 HaPnina Street

Ra'anana, 4321545

Israel

Social

What share of all stock conversation is about PLRZ?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% 0

Jul 7

A dedicated group for $PLRZ holders is now online, open to investors holding PolyRizon Ltd. stock to discuss the stock and get the latest information.
No other market-relevant information is available from this post.
The post does not mention any specific events, updates, or news related to PolyRizon Ltd. or its stock.

Generated by AI

Sentiment

Of the messages about PLRZ that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	0% -100	60% -8.75	83.13% +3.57
Bearish	—	100% new	40% +8.75	16.87% -3.57

Bullish· Feb 2

$PLRZ has broken key resistance levels, with a +31.36% surge to $15.12, confirming institutional accumulation and targeting $20.96.
The NASARIX™ usability study is advancing the regulatory pathway, providing a catalyst for Polyrizon Ltd.'s momentum and fueling a powerful technical breakout.
Polyrizon Ltd.'s stock is showing strong momentum, with a +36.22% surge to $15.68, and is on track to reach its next target of $22.43, driven by the company's progress in the FDA usability study for NASARIX™.

Bearish· Dec 8

The asset has a thin float, making it susceptible to large price movements.
A significant portion of the asset's volume is off-exchange, which may indicate a lack of liquidity.
The asset's price has fallen by as much as 30% and is experiencing heavy selling pressure.

Generated by AI

Topics

Of the messages about PLRZ that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	50%	76.92%	10.48%
Technical Analysis	—	50%	15.38%	19.33%
Controversies	—	0%	7.69%	0.04%
Analysts	—	0%	0%	33.84%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	36.32%

Announcements· Apr 15

Polyrizon Ltd. ($PLRZ) has closed a $3.5 million registered direct offering and concurrent private placement.
The offering will provide Polyrizon Ltd. with additional capital to support its business operations.
The company did not disclose any specific details on how the funds will be used.

Technical Analysis· Jan 4

The stock broke through the $10.12 resistance level on high volume, suggesting a potential major run.
The news about the nasal spray is adding fuel to the stock's upward momentum.
The target price in play is $19.64.

Generated by AI

Community

Of the messages about PLRZ, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	66.67%	16.61%
Newcomers	—	0%	33.33%	83.39%

Apr 15

Polyrizon Ltd. has closed a $3.5 million registered direct offering and concurrent private placement.
This funding round will help the company continue its growth and development in the biopharmaceutical industry.
The exact terms and details of the funding round are not specified in the provided information.

Generated by AI

Polyrizon

Social

Jul 7

Sentiment

Bullish· Feb 2

Bearish· Dec 8

Topics

Announcements· Apr 15

Technical Analysis· Jan 4

Community

Apr 15

News

Polyrizon enrolls first patient in U.S. allergy blocker trial

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

Polyrizon raises $4 million in registered direct offering

Polyrizon completes contracting for allergy blocker trial sites

Polyrizon completes contracting with all five clinical sites

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Also Discussed

Polyrizon Ltd.

Company Information

Location

News

Polyrizon enrolls first patient in U.S. allergy blocker trial

Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement

Polyrizon raises $4 million in registered direct offering

Polyrizon completes contracting for allergy blocker trial sites

Polyrizon completes contracting with all five clinical sites

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Also Discussed

Social

Jul 7

Sentiment

Bullish· Feb 2

Bearish· Dec 8

Topics

Announcements· Apr 15

Technical Analysis· Jan 4

Community

Apr 15